BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 11284030)

  • 1. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
    Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
    Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan.
    Ko BS; Tang JL; Lee FY; Liu MC; Tsai W; Chen YC; Wang CH; Sheng MC; Lin DT; Lin KH; Tien HF
    Am J Hematol; 2002 Dec; 71(4):291-9. PubMed ID: 12447959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique secondary chromosomal abnormalities are frequently found in the chronic phase of chronic myeloid leukemia in southern Vietnam.
    Phan TX; Hoang AV; Huynh VM; Nguyen KT; Nguyen TB; Huynh N; Pham QT; Tran VB; Tran VB; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jul; 168(1):59-68. PubMed ID: 16772122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.
    Reid AG; Tarpey PS; Nacheva EP
    Genes Chromosomes Cancer; 2003 Jul; 37(3):282-90. PubMed ID: 12759926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential display analysis of mRNAs in chronic myelogenous leukaemia.
    el-Awady MK; Abdalla NM; Salem AM; Samir S; Nour AM
    East Mediterr Health J; 2001; 7(4-5):707-15. PubMed ID: 15332769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: deletion on the derivative chromosome 9 may or not be present.
    Batista DA; Hawkins A; Murphy KM; Griffin CA
    Cancer Genet Cytogenet; 2005 Dec; 163(2):164-7. PubMed ID: 16337861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL.
    Onozawa M; Fukuhara T; Takahata M; Yamamoto Y; Miyake T; Maekawa I
    Ann Hematol; 2003 Sep; 82(9):593-5. PubMed ID: 12898186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular biology of chronic myeloid leukaemia.
    Melo JV
    Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2).
    Takeuchi M; Katayama Y; Okamura A; Yamamoto K; Shimoyama M; Matsui T
    Cancer Genet Cytogenet; 2007 Nov; 179(1):85-7. PubMed ID: 17981222
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
    Prejzner W
    Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
    Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A molecular cytogenetic study on chromosome anomalies of chronic myeloid leukemia].
    Zhu B; Shen X; Li C; Lai X; Li Y; Shi K; Feng H; Wang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Apr; 17(2):116-8. PubMed ID: 10751535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
    Lee YK; Kim YR; Min HC; Oh BR; Kim TY; Kim YS; Cho HI; Kim HC; Lee YS; Lee DS
    Cancer Genet Cytogenet; 2006 Apr; 166(1):65-73. PubMed ID: 16616113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.